This recommendation was made when prospective observational and randomized controlled trials in the highly active antiretroviral therapy (HAART) era demonstrated that discontinuation of PCP prophylaxis was safe when a sustained CD4 count >200 cells/μL was achieved [2]–[4]. The gene discussed is CD4; the disease is pneumocystosis.